Sleeve more cost effective than GLP-1

Posted On : October 30, 2026

Written by Ara Keshishian, MD, FACS, FASMBS
Last updated: October 30, 2026

Click the image or here to read the full article (General Surgery News, September 2026, page 22) »

GLP-1 medications cost less up front than metabolic and bariatric surgery. New research suggests surgery is still the better deal for payers over time. This is especially true for patients with class 2 or 3 obesity and type 2 diabetes, and for those on Medicaid. Dr. Michael A. Edwards of Mayo Clinic presented the study at the 2026 annual meeting of the American Society for Metabolic and Bariatric Surgery. His team used an all-payer claims database covering more than 80% of U.S. healthcare systems. They identified 90,769 patients treated between 2017 and 2023 with gastric bypass, sleeve gastrectomy, or at least two years of continuous GLP-1 use. The team matched surgical patients 1:1 with GLP-1 patients and compared total healthcare costs over the two years after treatment began.

Key findings

• Sleeve gastrectomy was the most cost-effective option. It saved an average of $12,794 compared with medication.
• The biggest gap was in the Medicaid group, where savings came to nearly $19,000.
• Gastric bypass saved about $4,000 on average compared with medication.
• GLP-1 costs were higher for every payer type, especially Medicare and Medicaid.

Why government payers see bigger differences

Dr. Edwards noted that Medicare and Medicaid patients often face socioeconomic and access-to-care barriers. That makes them more likely to rely on the ER, which raises the chance of hospital admission. Medicare and Medicaid also have less power than commercial insurers to negotiate prices.